---
title: "Director Kevin Bitterman Reports Disposal of Common Shares of Disc Medicine Inc. i"
description: "Kevin Bitterman, a Director at Disc Medicine, Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251249789.md"
published_at: "2025-08-01T20:33:25.000Z"
---

# Director Kevin Bitterman Reports Disposal of Common Shares of Disc Medicine Inc. i

> Kevin Bitterman, a Director at Disc Medicine, Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Disc Medicine Inc. published the original content via EDGAR on August 01, 2025.

Kevin Bitterman, a Director at Disc Medicine, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001415889-25-020863), on August 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IRON.US - Disc Medicine](https://longbridge.com/en/quote/IRON.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA 推迟了 Disc Medicine 的罕见病药物审批 | Disc Medicine Inc. 在收到美国食品药品监督管理局（FDA）关于其稀有疾病药物 bitopertin 的完整回应信（CRL）后，股价大幅下跌约 22%。FDA 对该药物在证明临床益处方面的有效性提出质疑，尽管有证据表明其能够 | [Link](https://longbridge.com/en/news/276114804.md) |
| FDA 向 Disc Medicine 的 bitopertin 新药申请（NDA）发出完整回复信 | FDA 向 Disc Medicine 发出了关于其 bitopertin 新药申请的完整回应信（CRL），该申请寻求加速批准。CRL 影响了监管路径和市场准入，因为 FDA 发现尽管有 PPIX 减少的证据，但整体血液无金属原卟啉 IX（ | [Link](https://longbridge.com/en/news/276055260.md) |
| 美国 FDA 拒绝批准 Disc Medicine 的罕见病药物 | 2 月 13 日（路透社）- Disc Medicine 周五表示，美国食品药品监督管理局拒绝批准其用于治疗一种罕见遗传疾病的药物，导致其股价下跌 31.6%，至 48.90 美元。该公司正在寻求对其实验性药物 bitopertin 的批准 | [Link](https://longbridge.com/en/news/275941119.md) |
| 美股盘中速递：Disc Medicine 涨 14.23%，FDA 审批新路径与分析师买入评级双重利好助力股价飙升 | Disc Medicine 涨 14.23%；艾伯维涨 0.46%，成交额达到 6.49 亿美元；吉利德科学跌 0.26%，成交额达到 4.01 亿美元；安进涨 1.21%，成交额达到 3.53 亿美元；福泰制药跌 2.77%，市值达到 1 | [Link](https://longbridge.com/en/news/276156879.md) |
| 美股盘前热门交易：ImmunityBio 盘前涨 7.32%；Disc Medicine 盘前涨 3.34% | ImmunityBio 盘前涨 7.32%；Disc Medicine 盘前涨 3.34%；TG-17 盘前涨 155.27%；Polaryx Therapeutics 盘前涨 49.79%；Leifras 盘前涨 36.78%。 | [Link](https://longbridge.com/en/news/276117215.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.